Navigation Links
Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Date:11/20/2013

ises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of our current compounds, AT-001, AT-002 and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability to obtain regulatory approval for our existing or future product candidates; the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key scientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act
'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
2. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
3. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
4. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
7. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
8. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
9. Aratana Therapeutics Completes $15 Million Series B Financing
10. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
11. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... release first half and second quarter 2015 financial results ... , 2015.  The Company will host a conference call ... provide a general business update. The conference ... and 1-412-902-4262 (International), and asking to join the "Intrexon ...
(Date:7/31/2015)... LAS VEGAS , July 31, 2015 /PRNewswire/ ... pharmacists seek resources that help them drive positive ... as a vital source of patient care in ... Pharmacy,s annual tradeshow and conference, AmerisourceBergen announced ... strengthen its Pharmacy Services Administration Organization and help ...
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... Yondelis(R) sales network across Western Europe, BRACKNELL, ... services agreement with PharmaMar, a subsidiary of Zeltia ... sales team in Western,Europe to promote Yondelis(R), PharmaMar,s ... marketing authorization, will be,responsible for marketing the drug., ...
... new data,demonstrating that the investigational drug lacosamide, with ... therapy,significantly reduced the frequency of seizures and was ... up,to 5.5 years. The results of the two ... today at the 61st annual meeting of the ...
... LIFE. "Fertility & Diet" (p. 54). The latest chapter,of ... research on,how foods impact the odds of getting pregnant. ... M.D., and Patrick,J. Skerrett, authors of the new book ... weight control play in conception and weigh in on,their ...
Cached Biology Technology:Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 2Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 3UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 2UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 3UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients 4NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 2NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 3NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 4NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 5
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... research into the Earth,s paleoclimate history by NASA,s Goddard ... the potential for rapid climate changes this century, including ... is not abated. By looking at how the ... insight into a fundamental question raised by ongoing human-caused ...
... MADISON -- Shifting a fraction of truck-borne freight onto trains ... Midwest, according to researchers at the University of WisconsinMadison. ... to Erica Bickford, a graduate student in UWMadison,s Nelson Institute ... go about 150 miles on a gallon of diesel fuel. ...
... Medical School have made an important discovery about the ... on our understanding of how proteins regulate appetite control ... Zammit, Head of Metabolic and Vascular Health at Warwick ... palmitoyltransferase 1A, (CPT1) has a switch which is thrown ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4For Midwesterners, more boxcars mean cleaner air 2
Biotin anti-human CD164...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: